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BACKGROUND: The purpose of this study was to describe the fracture incidence
and bone mineral density (BMD) evolution in a large cohort of post-menopausal
women with breast cancer after 3 years of aromatase inhibitor (AI) therapy.
PATIENTS AND METHODS: A prospective, longitudinal study in real-life setting.
Each woman had an extensive medical assessment, a biological evaluation, a BMD
measurement, and systematic spinal X-rays at baseline and after 3 years of AI
therapy. Women with osteoporosis at baseline (T-score < -2.5 and/or non-traumatic
fracture history) were treated by oral weekly bisphosphonates.
RESULTS: Among 497 women (mean age 63.8 ± 9.6 years) included in this study,
389 had a bone evaluation both at baseline and after 3 years of AI therapy: 267
women (mean age 61.2 ± 8.6) with no osteoporosis at baseline and 122 women
(mean age 67.2 ± 9.1) with osteoporosis at baseline justifying a weekly oral
bisphosphonate treatment. Women without bisphosphonates had a significant
decrease in spine BMD (-3.5%, P < 0.01), neck BMD (-2.0%, P < 0.01), and total hip
BMD (-2.1%, P < 0.01) over the 3 years but only 15 of them (5.6%) presented an
incident vertebral or non-vertebral fracture. In osteoporotic women treated with
bisphosphonates, spine and hip BMD were maintained at 3 years but 12 of them
(9.8%) had an incident fracture. These fractured women were significantly older
(74.1 ± 9.8 versus 66.5 ± 8.8) but also presented BMD loss during treatment
suggesting poor adherence to bisphosphonate treatment.
CONCLUSION: This real-life study confirmed that AIs induced moderate bone loss
and low fracture incidence in post-menopausal women without initial osteoporosis.
In women with baseline osteoporosis and AI therapy, oral bisphosphonates
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